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Abstract: Infections may constitute a serious complication in patients with chronic lymphocytic
leukemia (CLL). New treatment agents including obinutuzumab and ibrutinib have improved the
progression-free survival in CLL, and data suggest a similar overall infection risk and a limited
risk of opportunistic infections when compared to standard chemo-immunotherapy. Nevertheless,
cases of opportunistic infections including non-tuberculous mycobacterial (NTM) in CLL patients
have recently been published. We present a case of a 74-year old man with extensive prior CLL
treatment history, including most recently obinutuzumab. He developed an abscess of the psoas
muscle and inguinal lymphadenopathy. An inguinal node biopsy specimen showed infection with
Mycobacterium avium, confirmed by broad-spectrum mycobacterial PCR, M. avium-specific PCR,
and mycobacterial culture. This case and our literature review suggest that physicians should be
aware of opportunistic infections in patients with CLL. Diagnostic differentiation from CLL disease
progression, Richter’s transformation to aggressive lymphoma, and secondary malignancy relies
on histological and appropriate microbiological studies from biopsy material of affected organs.
Infection prophylaxis in CLL should be considered, including vaccinations and intravenous immune
globulin replacement.
Keywords: Mycobacterium avium; abscess; infection; chronic lymphocytic leukemia; non-tuberculous
mycobacteria; obinutuzumab; ibrutinib; immunosuppression
1. Introduction
Infection with Mycobacterium avium complex (MAC) is a rare complication in patients with chronic
lymphocytic leukemia (CLL), with four previous cases reported in the literature [1–4]. Here we present
a patient with CLL who developed a psoas abscess due to M. avium, after having received extensive
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previous CLL therapies and five months after first receiving treatment with obinutuzumab. This case
and our literature review suggest that physicians should be aware of opportunistic infections in
patients with CLL. Accurate diagnosis of progressive lymphadenopathy in CLL requires appropriate
biopsy material to be analysed microbiologically and histologically.
2. Case Report
A 60-year old man was diagnosed with CLL. He underwent extensive courses of CLL treatment,
which included chlorambucil, prednisone, fludarabine, rituximab, cyclophosphamide, bendamustin,
ofatumumab, and lenalidomide.
Nine years later, hypogammaglobulinemia and recurrent respiratory infections were noted, and
monthly intravenous immune globulin (IVIG) infusions were started. Four years later, progressive
generalized lymphadenopathy with bulky retroperitoneal masses, weight loss and malaise were
attributed to progressive CLL, and monthly infusions of obinutuzumab were given. Five months
later, the patient presented with edema and pain of his right leg, along with painful swelling in the
right groin despite regression of the generalized lymphadenopathy. Computed tomography (CT)
showed a significant increase of the retroperitoneal lymph node masses and a new, contrast-enhancing
fluid collection in the right psoas muscle extending to the groin (Figure 1). Bacterial culture of a
CT-guided inguinal node biopsy specimen remained sterile, while broad spectrum mycobacterial
PCR, M. avium-specific PCR, and mycobacterial culture were all positive for M. avium. Histological
examination showed necrotic, histiocyte-predominant inflammation with numerous acid-fast bacilli
but no evidence of Richter’s transformation to an aggressive lymphoma. External catheter drainage of
the abscess was done for 8 weeks. CLL treatment was interrupted.
The isolate was susceptible in vitro to clarithromycin and rifampicin (minimal inhibitory
concentrations, 4 mg/L and 20 mg/L, respectively). Therapy with rifampicin 600 mg/day, ethambutol
1000 mg/day and clarithromycin 500 mg/day was given. The second cycle of obinutuzumab was
delayed by three months due to the infectious complication. The third cycle was started on time
but was terminated early due to progression of the CLL. Eight months into M. avium therapy,
complete remission of the abscess without any relapse were noted on CT. However, generalized
lymphadenopathy re-appeared. M. avium treatment with rifampicin, ethambutol, and clarithromycin
was continued and ibrutinib was started, which again led to a major response of the lymphadenopathy.
The initial dose of ibrutinib was reduced to 280 mg due to low blood counts and the risk of potential
drug interactions with increased blood levels of ibrutinib. The second and third cycles of ibrutinib
were started with 420 mg for 2 weeks and reduced to 280 mg for the rest of the cycle due to low
platelet counts. Later cycles were given at the standard dose for CLL, i.e., 420 mg without evidence
of enhanced hematotoxicity despite the combination with the antimycobacterial agents. Blood level
measurements for ibrutinib were not done.
Unfortunately, the patient died 10 months after initiating antimycobacterial treatment, in the
setting of massive pleural hemorrhage and bleeding into the mediastinal lymph nodes. At autopsy,
no macroscopic or histological evidence of the infection with M. avium was found in the area of the
original abscess or elsewhere.
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Figure 1. Mycobacterium avium psoas abscess and inguinal lymphadenitis in a patient with chronic 
lymphocytic leukemia (CLL). (A) Computed tomography with intravenous and oral contrast, done at 
the time of initiation of intravenous immune globulin (IVIG) replacement, demonstrates normal and 
symmetric psoas muscle appearance (arrowhead), without abscess formation. (B) Large, septated 
abscess (dashed arrows) located within the right psoas muscle (arrowhead), of which biopsy material 
grew M. avium in culture. (C) One month later, notable reduction in psoas abscess volume 
(arrowhead) after introduction of computed tomography (CT)-guided percutaneous pigtail catheter 
drain (arrow). (D) CT scout image corresponding to axial image C, demonstrating the course of the 
percutaneous pigtail catheter drain (arrow). 
3. Literature Review and Discussion 
Lymphadenopathy in patients with CLL has a broad differential diagnosis, which most 
commonly includes progressive or treatment-unresponsive CLL, but also Richter’s transformation to 
aggressive lymphoma, second malignancies, and infectious lymphadenitis [4]. When adenopathy is 
not pronounced and the patient is well, without systemic symptoms or cytopenias, successful 
treatment with a course of antibiotics (without making a specific diagnosis) has been recorded [4]. 
However, when lymphadenopathy is progressive or generalized, or when the patient is systemically 
ill, accurate diagnosis becomes important, and typically requires lymph node biopsy material to be 
sent for histological and microbiological (including mycobacterial) studies.  
3.1. Infections with Non-Tuberculous Mycobacteria (NTM) 
NTM are ubiquitous in the environment, are not considered to be transmitted from person to 
person, and their incidence seems to be increasing in several geographic locations [5–7]. The lungs 
are the most common site of NTM infections, with 90% of positive NTM cultures derived from 
pulmonary secretions. Approximately half of these cases are considered true infection and half are 
attributed to respiratory tract colonization [5,6,8]. M. avium complex (MAC) is by far the most 
common NTM species recovered from the lungs. Immunosuppressive treatment is recorded in 
approximately 25% of patients with NTM infections [8], and in immunocompromised individuals, 
extrapulmonary and disseminated NTM infections may commonly occur [8,9]. In NTM patients who 
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3. Literature Review and Discussion
Lymphadenopathy in patients with CLL has a broad differential diagnosis, which most commonly
includes progressive or treatment-unresponsive CLL, but also Richter’s transformation to aggressive
lymphoma, second malignancies, and infectious lymphadenitis [4]. When adenopathy is not
pronounced and the patient is well, without systemic symptoms or cytopenias, successful treatment
with a course of antibiotics (without making a specific diagnosis) has been recorded [4]. However,
when lymphadenopathy is progressive or generalized, or when the patient is systemically ill, accurate
diagnosis becomes important, and typically requires lymph node biopsy material to be sent for
histological and microbiological (including mycobacterial) studies.
3.1. Infections with Non-Tuberculous Mycobacteria (NTM)
NTM are ubiquitous in the environment, are not considered to be transmitted from person to
person, and their incidence seems to be increasing in several geographic locations [5–7]. The lungs are
the most common site of NTM infections, with 90% of positive NTM cultures derived from pulmonary
secretions. Approximately half of these cases are considered true infection and half are attributed
to respiratory tract colonization [5,6,8]. M. avium complex (MAC) is by far the most common NTM
species recovered from the lungs. Immunosuppressive treatment is recorded in approximately 25%
of patients with NTM infections [8], and in immunocompromised individuals, extrapulmonary and
disseminated NTM infections may commonly occur [8,9]. In NTM patients who are not receiving
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immunosuppressive treatment, common predisposing conditions may include chronic obstructive
pulmonary disease and bronchiectasis [5,8].
There are four previously reported cases of MAC infection in patients with CLL in the literature
(Table 1). These reports have included patients with various prior CLL therapies who developed MAC
lymphadenitis [1], small bowel infection [2], or disseminated cutaneous disease [3] (Table 1). One
patient developed recurrent MAC lymphadenitis that was first noted before any CLL therapy was
given [4].
Table 1. Reported cases of Mycobacterium avium complex (MAC) infection in patients with CLL.
Age at
CLL
(year)
Age at
MAC
(year)
Sex
Clinical
Manifestations
of MAC
Infection
Site of MAC
Detection
CLL Treatment before MAC
Diagnosis Outcome Ref.
60 74 Male
retroperitoneal
and inguinal
lymphadenitis,
psoas abscess
Inguinal
lymph node
biopsy
chlorambucil, prednisone,
fludarabine, rituximab,
cyclophosphamide,
bendamustin, ofatumumab,
lenalidomide; intravenous
immune globulin;
obinutuzumab
MAC
successfully
treated,
patient dies
several
months later
present
case
38 46 Male lymphadenitis lymph nodebiopsy alemtuzumab alive [1]
41 55 Male
lymphadenitis,
small bowel
infection
n/a
cyclophosphamide/
oncovine/prednisone
chemotherapy
alive [2]
49 59 Male
disseminated
cutaneous
disease
skin biopsy
fludarabine, prednisone,
cyclophosphamide,
rituximab, alemtuzumab
died [3]
n/a n/a Male lymphadenitis lymph nodebiopsy none alive [4]
Clinical recognition of MAC infection can be difficult. In our patient, progressive CLL or
Richter’s transformation to an aggressive lymphoma was initially suspected as the cause of increasing
retroperitoneal lymphadenopathy. MAC infection was only diagnosed when the newly appearing groin
mass was biopsied; mycobacterial cultures were only requested after infectious diseases consultation
was obtained, when standard cultures of the biopsy material remained without bacterial growth.
In addition to MAC, other NTM infections have been recorded in CLL patients, including
infections with M. chelonae [10–12], M. marinum [13,14], M. szulgai [15], M. fortuitum [16] and
M. genavense [17] (Table 2). These patients were affected mostly by disseminated cutaneous lesions
(n = 6, [10–15]) or nodular pulmonary infections (n = 2, [13,16]). One patient presented with multifocal
osteomyelitis and skin lesions [15].
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Table 2. Reported cases of non-tuberculous mycobacterial NTM infections other than M. avium in
patients with CLL.
Age at
CLL
(year)
Age at
NTM
(year)
Sex NTMSpecies
Clinical
Manifestations of
NTM Infection
Site of NTM
Detection
CLL Treatment before
NTM Diagnosis Outcome Ref.
48 58 F M. chelonae disseminatedcutaneous disease skin biopsy
methylprednisolone
and other 5 non
specified agents
alive [10]
74 85 M M. chelonae skin lesions onarms and legs skin biopsy
bendamustin,
rituximab, fludarabine alive [11]
67 74 M M. chelonae skin lesions skin biopsy
chlorambucil,
fludarabine,
cyclophosphamide,
alemtuzumab
alive [12]
62 n/a M M. marinum
erythematous
cutaneous
nodules,
pulmonary nodule
skin biopsy prednisolone,ciclosporin died [13]
57 64 M M. marinum skin lesions skin biopsy
fludarabine,
cyclophosphamide,
rituximab
alive [14]
61 62 M M. fortuitum pulmonarynodules sputum
chlorambucile,
fludarabine died [16]
62 79 and83 F
M.
genavense lymphadenitis
blood
culture and
bone
marrow
biopsy
chlorambucil,
prednisone died [17]
59 66 F M. szulgai
multifocal
osteomyelitis,
cutaneous lesions
bone biopsy fludarabine,chlorambucil died [15]
3.2. Infectious Complications in CLL
Infectious complications are well-recorded in patients with CLL and may be responsible for more
than half of all deaths in these patients [18–21]. CLL patients also have an increased incidence of second
malignancies, suggesting impaired immune surveillance [18]. Infections in CLL have been attributed to
several mechanisms, which may coexist in an individual patient, including patient factors (increasing
age, comorbidities), and inherent immune dysfunction related to CLL itself (hypogammaglobulinemia,
dysfunction of T-cells, NK-cells, and dendritic cells, complement defect, phagocyte dysfunction) [18,22].
The relevance of such inherent immunological dysfunction in CLL is documented by the published
case of a patient who developed M. avium lymphadenitis in the setting of no prior CLL treatment [4].
However, the precise impact of these immunological defects on infection risk in CLL, and their
reversibility after CLL treatment has been difficult to quantify [18].
The key risk factor for infectious complications in CLL seems to be the number and type of
immunosuppressive agents previously used for CLL treatment [18,19,21]. For example, infectious
complications may occur in the setting of neutropenia or T-cell dysfunction which may follow
treatment with bendamustine, alemtuzumab, obinutuzumab, rituximab, or fludarabine [18,20].
The immunosuppressive effects of CLL therapies (e.g., alemtuzumab, fludarabine, rituximab) may be
profound and prolonged, i.e., they may persist for years after therapy is discontinued. It is thus likely
that the cumulative effect of different CLL treatment agents given over many years predisposed our
patient to immune dysfunction and opportunistic NTM infection.
The initial presentation of infections in CLL typically includes pneumonia or bacteremia caused
by encapsulated bacteria, with herpes viruses, urinary tract, central nervous system, and soft tissue
infections occurring less frequently. Viral infections appear more often in patients treated with
purine analogues or autologous stem cell transplantation. Infection prevention strategies in CLL
should be selected on a case by case basis and may include vaccination (seasonal influenza vaccine,
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pneumococcal vaccine), intravenous immune globulin replacement in the setting of recurrent bacterial
infections, consideration of hepatitis B antiviral treatment to prevent reactivation, and pneumocystis
prophylaxis [19].
3.3. Obinutuzumab
Obinutuzumab is a humanized monoclonal antibody that acts as an immunomodulator by
targeting CD20 on the surface of B-lymphocytes. In a randomized trial of patients with previously
untreated CLL, obinutuzumab plus chlorambucil was associated with improved progression-free
survival compared to rituximab plus chlorambucil [23]. Importantly, patients that received
obinutuzumab more frequently had neutropenia, but the occurrence of serious infections was similar
(11–14% in each study arm). Infections that occurred after treatment with obinutuzumab were
mostly bacterial.
To our knowledge, ours is the first report of a mycobacterial infection following obinutuzumab
administration in a CLL patient. The generalized lymphadenopathy significantly regressed
after starting obinutuzumab treatment, and retroperitoneal/unilateral inguinal lymphadenopathy
subsequently increased, suggesting the need for a diagnostic biopsy which led to the diagnosis of M.
avium infection. Therefore, it appears unlikely that disseminated M. avium infection was already
present before obinutuzumab was started. However, the significance of obinutuzumab treatment
in contributing to M.avium infection in our patient is unclear, given the long history of CLL and
numerous immunosuppressive treatments the patient had previously received.
3.4. Ibrutinib
Another target-specific agent recently introduced for treating CLL is ibrutinib [24]. It irreversibly
inhibits Bruton’s tyrosine kinase, which is a key enzyme involved in the maturation and
function of B-lymphocytes. Ibrutinib was given to our patient after re-appearance of generalized
lymphadenopathy despite obinutuzumab treatment and following successful antimicrobial therapy
of the M. avium psoas abscess. Ibrutinib may also be beneficial in patients over 65 years of age with
previously untreated CLL and was recorded to be more effective regarding progression-free survival
compared to chemoimmunotherapy with bendamustine plus rituximab [25].
Ibrutinib is typically well tolerated for extended periods in many patients with CLL and has
not been associated with a higher infection risk than with comparator CLL treatments, neither in
combination with alkylating drugs or anti-CD20 monoclonal antibody therapy nor as monotherapy
in treatment-naïve CLL patients [18,22]. Occasional case reports of CLL patients with infections
after ibrutinib therapy have included lower respiratory tract infections and bacterial pneumonia.
Opportunistic infections have only rarely been reported after ibrutinib, and have included cases of
Pneumocystis jirovecii pneumonia, disseminated fusariosis, cryptococcal meningitis, and invasive
aspergillosis [18].
4. Conclusions
• Our case and our literature review illustrate that physicians should be aware of opportunistic
infections in patients with CLL.
• Infectious complications may be difficult to recognize clinically. Appropriate biopsy material
from affected lymph nodes should be obtained. The key to diagnosis of opportunistic infection
is microbiological confirmation and histological exclusion of secondary malignancies, Richter’s
transformation, and progressive CLL.
• Diagnosis of NTM infection relies on mycobacterial PCR and culture done on biopsy material (or
broncho-alveolar lavage fluid when there is respiratory involvement).
• Infection prophylaxis including vaccinations or intravenous immune globulin replacement should
be considered in all CLL patients when appropriate.
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